What are you looking for?
Patients with diabetic macular edema (DME) who maintained stable vision despite being lost to follow-up experienced suboptimal responses after restarting anti-VEGF therapy, according to a study. Researchers evaluated patients with center-involved DME (n = 976) who had been lost to follow-up for at least 6 months and later resumed anti-VEGF treatment. After a median absence... ...
Adding an artificial intelligence (AI)–based optical coherence tomography (AI-OCT) system to diabetic retinopathy screening substantially reduced false-positive referrals for diabetic macular edema...
Faricimab and aflibercept 2 mg produced comparable short-term visual and anatomical outcomes in patients with diabetic macular oedema (DMO), according to a...
The U.S. Food and Drug Administration has approved extended dosing intervals for EYLEA HD (aflibercept), allowing treatment up to every 20 weeks...
Patients with diabetic macular edema (DME) treated with simultaneous intravitreal dexamethasone and aflibercept experienced sustained improvements in both visual acuity and retinal thickness over a 24-month follow-up period, with relatively...
Our most-read retinal coverage of 2025 highlights how higher-dose therapies and real-world evidence are refining treatment approaches for AMD and diabetic macular edema. From registry and global study data informing...
Intravitreal aflibercept (IVA) is effective for treating diabetic macular edema (DME) in eyes with or without prior pars plana vitrectomy (PPV), with similar visual and anatomical improvements and comparable treatment...
A new systematic review and meta-analysis highlights that anti-VEGF therapy leads to measurable improvements in quality of life for patients with diabetic macular edema (DME), though the overall gains remain...
Vitrectomy for clinically non-tractional diabetic macular edema (DME) provides generally good and stable visual outcomes that are maintained for 10 years, according to a study. However, prospective studies are still...
A post-hoc analysis of the DRCR Protocol T study examined changes in hard exudates following anti-vascular endothelial growth factor therapy for diabetic macular edema and their relationship to vision outcomes....
Patients receiving intravitreal injections for diabetic macular edema (DME), age-related macular degeneration (AMD), or retinal vein occlusion (RVO) experience varying levels of anxiety and depression, influenced by disease type, sex,...
Ashkan Abbey, MD, of Texas Retina Associates, spoke with Ophthalmology 360 at AAO 2025 about the latest clinical updates on the investigational treatment vorolanib or EYP-1901. Phase 3 trials are...